Market Overview

MediciNova Initiates Cooperative Phase 2b Trial of MN-166 in Progressive Multiple Sclerosis

MediciNova (NASDAQ: MNOV) and the Jasdaq Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the funding and regulatory approvals of a NIH-based grant for a Phase 2b trial of MN-166 (ibudilast) in subjects with progressive multiple sclerosis (progressive MS). The principal investigator will be Robert Fox, M.D., M.S., FAAN, Staff Neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic.

The grant is for a funded cooperative effort by the NeuroNEXT clinical trial network within the National Institute of Neurological Disorders and Stroke (NINDS) at the U.S. National Institutes of Health (NIH). The collaboration additionally includes multiple academic centers, MediciNova and advocacy support from the National Multiple Sclerosis Society.

See full press release

Posted-In: News Guidance Contracts Management Global

 

Related Articles (MNOV)

Around the Web, We're Loving...

Get Benzinga's Newsletters